 | Up a level |
Rottenburger, Christof; Hentschel, Michael; Fürstner, Markus; McDougall, Lisa; Kottoros, Danijela; Kaul, Felix; Mansi, Rosalba; Fani, Melpomeni; Vija, A Hans; Schibli, Roger; Geistlich, Susanne; Behe, Martin; Christ, Emanuel R; Wild, Damian (2024). In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI research, 14(37) Springer 10.1186/s13550-024-01101-w
Rottenburger, Christof; Nicolas, Guillaume P; McDougall, Lisa; Kaul, Felix; Cachovan, Michal; Vija, A Hans; Schibli, Roger; Geistlich, Susanne; Schumann, Anne; Rau, Tilman; Glatz, Kathrin; Behe, Martin; Christ, Emanuel R; Wild, Damian (2020). Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study. Journal of nuclear medicine, 61(4), pp. 520-526. Society of Nuclear Medicine 10.2967/jnumed.119.233031
Domnanich, Katharina Anna; Eichler, Robert; Müller, Cristina; Jordi, Sara Laura; Yakusheva, Vera; Braccini, Saverio; Behe, Martin; Schibli, Roger; Türler, Andreas; van der Meulen, Nicholas P. (2017). Production and separation of 43Sc for radiopharmaceutical purposes. EJNMMI Radiopharmacy and Chemistry, 2(1) Springer 10.1186/s41181-017-0033-9
Müller, Cristina; Fischer, Eliane; Behe, Martin; Köster, Ulli; Dorrer, Holger Johann; Reber, Josefine; Haller, Stephanie; Cohrs, Susan; Blanc, Alain; Grünberg, Jürgen; Bunka, Maruta; Zhernosekov, Konstantin; van der Meulen, Nicholas; Johnston, Karl; Türler, Andreas; Schibli, Roger (2014). Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice. Nuclear medicine and biology, 41 Suppl, e58-65. Elsevier 10.1016/j.nucmedbio.2013.11.002
Wild, Damian; Fani, Melpomeni; Behe, Martin; Brink, Ingo; Rivier, Jean E F; Reubi, Jean-Claude; Maecke, Helmut R; Weber, Wolfgang A (2011). First clinical evidence that imaging with somatostatin receptor antagonists is feasible. Journal of nuclear medicine, 52(9), pp. 1412-7. New York, N.Y.: Society of Nuclear Medicine 10.2967/jnumed.111.088922
Wicki, Andreas; Wild, Damian; Storch, Daniel; Seemayer, Christian; Gotthardt, Martin; Behe, Martin; Kneifel, Stefan; Mihatsch, Michael J; Reubi, Jean-Claude; Mäcke, Helmut R; Christofori, Gerhard (2007). [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clinical cancer research, 13(12), pp. 3696-705. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-06-2965
